Ed Harlow
 |
Ed Harlow | |
|---|---|
| Known for | Retinoblastoma protein |
| Scientific career | |
| Institutions | Harvard Medical School |
Ed Harlow (born 1952) is an American molecular biologist.
Harlow received the Ph.D. degree from the Imperial Cancer Research Fund Laboratories in London.
Harlow is professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.
He has been associate director of the Dana–Farber Cancer Institute as well as research director of the Massachusetts General Hospital Cancer Center and the National Cancer Institute.
From 2009 to 2011 he was Chief Scientific Officer at Constellation Pharmaceuticals.
Among Harlow's discoveries was the demonstration that the retinoblastoma protein interacts with viral transforming proteins, thereby linking tumor viruses with the cell cycle. He is also the author, with David Lane, of "Using antibodies: a laboratory manual." (1999).[1]
Dr. Harlow has trained scientists in the field of molecular biology and oncology, including Nicholas Dyson (Professor at Harvard Medical School and Scientific Director of the Massachusetts General Hospital Cancer Center), Jacqueline Lees (Professor of Biology at MIT and associate director of the Koch Institute), Joshua LaBaer (Virginia G. Piper Chair in Personalized Medicine at Arizona State University and Director of the Biodesign Institute), Matthew Meyerson (Professor of Pathology at the Dana–Farber Cancer Institute and Harvard Medical School and Senior Associate Member of the Broad Institute), Li-Huei Tsai (Picower Professor of Neuroscience at MIT and Director of the Picower Center for Learning and Memory), and Marc Vidal (Director of the Center for Cancer Systems Biology at the Dana–Farber Cancer Institute).[citation needed]
Publications
[edit]- Dyson, Nicholas, et al. "The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product." Science 243.4893 (1989): 934–937.[2]
- Whyte, Peter, et al. "Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product." (1988): 124–129.[3]
- LaBaer, Joshua, et al. "New functional activities for the p21 family of CDK inhibitors." Genes & development 11.7 (1997): 847–862.[4]
- Buchkovich, Karen, Linda A. Duffy, and Ed Harlow. "The retinoblastoma protein is phosphorylated during specific phases of the cell cycle." Cell 58.6 (1989): 1097–1105.[5]
- van den Heuvel, Sander, and Ed Harlow. "Distinct roles for cyclin-dependent kinases in cell cycle control." Science 262.5142 (1993): 2050–2054.[6]
- Harlow, E. D., et al. "Monoclonal antibodies specific for simian virus 40 tumor antigens." Journal of Virology 39.3 (1981): 861–869.[7]
- Tsai, Li-Huei, et al. "p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5." (1994): 419–423.[8]
- Meyerson, Matthew, et al. "A family of human cdc2-related protein kinases." The EMBO Journal 11.8 (1992): 2909.[9]
- Whyte, Peter, Nicola M. Williamson, and E. D. Harlow. "Cellular targets for transformation by the adenovirus E1A proteins." cell 56.1 (1989): 67–75.[10]
Awards
[edit]- National Academy of Sciences, Member[11]
- Alfred P. Sloan, Jr. Prize[12]
- American Academy of Arts and Sciences, Member[13]
- Dickson Prize in Medicine[14]
- National Academy of Medicine, Member
- American Cancer Society, Medal of Honor[15]
References
[edit]- ^ Harlow, E (1998). Using antibodies: a laboratory manual. ISBN 0879695447.
- ^ Dyson, N (1989). "The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product". Science. 243: 934–7. doi:10.1126/science.2537532. PMID 2537532.
- ^ Whyte, P (1988). "Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product". Nature. 334: 124–9. doi:10.1038/334124a0. PMID 2968522.
- ^ LaBaer, J (1997). "New functional activities for the p21 family of CDK inhibitors". Genes Dev. 11: 847–62. doi:10.1101/gad.11.7.847. PMID 9106657.
- ^ Buchkovich, K (1989). "The retinoblastoma protein is phosphorylated during specific phases of the cell cycle". Cell. 58: 1097–105. doi:10.1016/0092-8674(89)90508-4. PMID 2673543.
- ^ van den Heuvel, S (1993). "Distinct roles for cyclin-dependent kinases in cell cycle control". Science. 262: 2050–4. doi:10.1126/science.8266103. PMID 8266103.
- ^ Harlow, E (1981). "Monoclonal antibodies specific for simian virus 40 tumor antigens". J Virol. 39: 861–9. PMC 171319. PMID 6169844.
- ^ Tsai, L (1994). "p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5". Nature. 371: 419–23. doi:10.1038/371419a0. PMID 8090221.
- ^ Meyerson, M (1992). "A family of human cdc2-related protein kinases". EMBO J. 11: 2909–17. doi:10.1002/j.1460-2075.1992.tb05360.x. PMC 556772. PMID 1639063.
- ^ Whyte, P (1989). "Cellular targets for transformation by the adenovirus E1A proteins". Cell. 56: 67–75. doi:10.1016/0092-8674(89)90984-7. PMID 2521301.
- ^ "Ed Harlow". www.nasonline.org. Retrieved 2020-04-30.
- ^ "Four Researchers Garner Annual GM Foundation Prizes". The Scientist Magazine®. Retrieved 2020-04-30.
- ^ "Edward Everett Harlow, Jr". American Academy of Arts & Sciences. Retrieved 2020-04-30.
- ^ "Previous Winners of the Dickson Prize in Medicine | Dickson Prize in Medicine | University of Pittsburgh". www.dicksonprize.pitt.edu. Retrieved 2020-04-30.
- ^ "Advocate Lance Armstrong, Scientists Edward E. Harlow, Arnold J. Levine, and Marvin Zelen to Receive American Cancer Society Highest Honor for Outstanding Contributions to Cancer Fight - Nov 19, 2009". American Cancer Society MediaRoom. Retrieved 2020-04-30.
